⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IOVA News
Iovance Biotherapeutics, Inc. Common Stock
PROLEUKIN Clinical and Commercial Intelligence Report 2026-2034: IL-2 Combination Research Expands Market Potential
globenewswire.com
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
globenewswire.com
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
IOVA
Global Cancer Immunotherapy Market Report 2026 | Industry to Reach $311.43 Billion by 2031, Driven by Precision Oncology and Cell Therapy Innovation
globenewswire.com
AMGN
AZN
BMY
MRK
PFE
NVS
GSK
LLY
ABBV
JNJ
REGN
SNY
BE
BNTX
MRNA
IOVA
Form 8-K
sec.gov
IOVA
Why Investors Are Watching These Healthcare Movers
globenewswire.com
CLRO
NTHI
IOVA
ENSC
VANI
Form 8-K
sec.gov
IOVA
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
globenewswire.com
IOVA
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
globenewswire.com
IOVA
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
globenewswire.com
IOVA